PRESENTATION

Paulo Rodrigues-Santos is the Head of Research and Science Communication at the Institute of Immunology, Invited Assistant at the Faculty of Medicine and Director of the Immunology and Oncology Laboratory of the Center for Neuroscience and Cell Biology, University of Coimbra (Portugal).

PRS developed his work on Immunogenetics under the supervision of Professor Gottfried Mauff at Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine, University of Cologne, Germany. He worked on Transplantation Immunobiology as Head of the Functional Genomics Laboratory at the Center for Histocompatibility of the Centre (Coimbra, Portugal).

PRS was Chair of the Education Committee of the European Federation for Immunogenetics (EFI), Board Member of the European Complement Network (ECN) and Vice-President of the Portuguese Society for Immunology (SPI). Currently, PRS is the President of the Supervisory Board of SPI (2024-2027).

He is Founder and Coordinator of the Portuguese Group of Immuno-Oncology (gpI-O), a joint working group of the Portuguese Society for Oncology (SPO) and the Portuguese Society for Immunology (SPI).

PRS is an Editorial Board Member of Discover Immunity, an Associate Editor for Cancer Immunity and Immunotherapy at Frontiers in Immunology and  Frontiers in Oncology; an Associate Editor for Immunogenetics at Frontiers in Genetics; an Associate Editor for Aging and the Immune System at Frontiers in Aging; and a Topical Advisory Panel member of the International Journal of Molecular Sciences.

ORCID: 0000-0001-7519-1620
ResearchID: M-3175-2013
Loop profile: 55546
Ciência ID: 4311-1E7F-9AA8

VISION

Our studies are primarily concerned with the signal integration and function-switch of Innate Lymphoid Cells (ILC)​, particularly natural killer (NK) cells.

Currently, research on immune monitoring and immunological modulation for cancer therapy is focused on the dynamic growth of innate immune cells and the functional tuning of cell receptors in malignant diseases.

Our main objective is to develop and apply innate cell-based immunotherapy to human cancer cells in a therapeutic setting.

Leaping forward translational immunology

"No one understands the wonders that the immune system can perform better than immunologists, so translation now represents not only an opportunity but also a mandate for immunologists."

Drew M Pardoll

Johns Hopkins Univ. School of Medicine, USA.

EDITORIAL CONTRIBUTIONS

Frontiers in Immunology

Frontiers in Oncology

Special Issue
​"Peripheral Blood-Based Biomarkers for Immune Monitoring of Cancer and Cancer Therapy​"

Guest Editors

Paulo Rodrigues Santos, José Manuel Casanova & Raquel Tarazona

More info

International Journal of Molecular Sciences

Special Issue
​"Next-Generation Cancer Immunotherapies: Tracking, Targeting and Reprogramming the Immune Response​"

Guest Editor

Paulo Rodrigues Santos

More info

Get social